

Subject: Intensity Modulated Radiation Therapy (IMRT)		Original Effective Date: 3/25/2015
Policy Number: MCP-225	Revision Date(s): 6/24/2015, 3/8/2018	
Review Date: 6/24/2015; 12/16/2015, 9/15/2016, 6/22/2017; 3/8/2018, 9/18/19		
MCPC Approval Date: 3/8/2018, 9/18/19		

DISCLAIMER

This Molina Clinical Policy (MCP) is intended to facilitate the Utilization Management process. It expresses Molina's determination as to whether certain services or supplies are medically necessary, experimental, investigational, or cosmetic for purposes of determining appropriateness of payment. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered (i.e., will be paid for by Molina) for a particular member. The member's benefit plan determines coverage. Each benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their providers will need to consult the member's benefit plan to determine if there are any exclusion(s) or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and a member's plan of benefits, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of a State, the Federal government or CMS for Medicare and Medicaid members. CMS's Coverage Database can be found on the CMS website. The coverage directive(s) and criteria from an existing National Coverage Determination (NCD) or Local Coverage Determination (LCD) will supersede the contents of this Molina Clinical Policy (MCP) document and provide the directive for all Medicare members.¹

DESCRIPTION OF PROCEDURE/SERVICE/PHARMACEUTICAL ⁵⁴

Intensity-modulated radiation therapy (IMRT) is a specialized form of external beam radiation treatment that involves modulation of radiation beam intensities within treatment fields to obtain more conformal dose delivery around the target(s) of irradiation. IMRT uses computer software, CT images, and magnetic resonance imaging (MRI) to modulate the intensity of the overlapping radiation beams projected on the target and to use multiple-shaped treatment fields. It uses a device (a multileaf collimator, MLC) which, coupled to a computer algorithm, allows for treatment planning. The radiation oncologist delineates the target on each slice of a CT scan and specifies the target's prescribed radiation dose, acceptable limits of dose heterogeneity within the target volume, adjacent normal tissue volumes to avoid, and acceptable dose limits within the normal tissues. Based on these parameters and a digitally reconstructed radiographic image of the tumor and surrounding tissues and organs at risk, computer software optimizes the location, shape, and intensities of the beams ports, to achieve the treatment plan's goals. Increased conformality may permit escalated tumor doses without increasing normal tissue toxicity and thus may improve local tumor control, with decreased exposure to surrounding normal tissues, potentially reducing acute and late radiation toxicities. Better dose homogeneity within the target may also improve local tumor control by avoiding under dosing within the tumor and may decrease toxicity by avoiding overdosing. The benefits of IMRT are the greatest for patients with tumor targets that are concave, and where normal tissues around it are clinically important.

1. Intensity Modulated Radiation Therapy (IMRT) may be considered medically necessary and may be authorized when sparing the surrounding normal tissue is essential and one of the following conditions is present: [ONE]

- Important dose limiting structures adjacent to, but outside the planned treatment volume (PTV), are sufficiently close and require IMRT to assure safety and morbidity reduction; or
- An immediately adjacent volume has been irradiated and abutting portals must be established with high precision; or
- Gross Tumor Volume (GTV) margins are concave or convex and in close proximity to critical structures that must be protected to avoid unacceptable morbidity; or
- Only IMRT techniques would decrease the probability of grade 2 or grade 3 radiation toxicity as compared to conventional radiation in greater than 15% of radiated similar cases

AND

2. Documentation is submitted by the treating physician that outlines the medical necessity for IMRT instead of using conventional or 3-dimensional treatment planning and delivery for any of the following conditions: [ONE]

- Central nervous system (CNS) tumors (primary or metastatic lesions) with close proximity to the optic nerve, lens, retina, optic chiasm, cochlea, or brain stem including any of the following:
[ONE] ⁵⁻¹⁸⁻²⁶⁻³²⁻³³⁻⁴⁸
 - Brain including cranial nerves and meninges,
 - Spinal cord including spinal meninges
- Esophageal Cancer ^{14-29-30-31 61 63}
- Head and neck cancer ^{4-11-16-45-59 61 63} including but not limited to any of the following: [ONE]
 - Hypopharynx; or
 - Laryngeal (advanced); or
 - Nasopharynx; or
 - Oral cavity; or
 - Oropharynx; or
 - Orbits; or
 - Paranasal sinuses and nasal cavity; or
 - Salivary glands
 - Tracheal Cancer ⁵⁷

- Prostate Tumors: [ONE] ³⁻²⁰⁻²¹⁻²⁵⁻⁴²⁻⁴⁷
 - Primary prostate carcinoma in individuals with an intact prostate and non-metastatic prostate cancer; or
 - After radical prostatectomy as adjuvant/salvage therapy and no evidence of disseminated disease; or
 - For symptomatic, metastatic prostate cancer when the target disease is within, or immediately adjacent to, previously irradiated tissue, and in selected solitary metastatic lesions

- Thoracic malignancies, including: [ONE]
 - Lung tumors ¹⁰⁻²²⁻³⁴⁻³⁵⁻³⁸⁻⁵⁰ when a critical anatomical structure (such as cardiac or spine) is located in the radiation field and there is documented significantly impaired or limited pulmonary function; or
 - Left breast tumors: ^{7-8-17-39-46 61 63}
 - when there is documented risk to immediately adjacent cardiac and pericardial structures; or
 - when 3D conformal produces focal regions with dose variation greater than 10% of target and for patients with target tissues that include the far medial chest wall, internal mammary nodal area or sternum (post-mastectomy or post lumpectomy)
 - Mediastinal tumors when radiation is indicated ²⁸

- Cervical or Uterine cancer in patients who have had a hysterectomy with intact cervix when the para-aortic lymph nodes require treatment ^{13-15-40 61 63}

- Rectal/Anal cancer in unique clinical situations such as re-irradiation of previously treated recurrent disease or unique anatomical situations ^{9-12-23-36-37-43-49 61}

- Other Abdominal and Pelvic tumors on a case by case basis only when medical necessity documentation is submitted to indicate that conventional or 3-dimensional treatment planning and delivery cannot be safely performed

- Soft tissue sarcoma when an R1 or R2 resection is anticipated to increase the therapeutic ratio ⁶¹

- Repeat irradiation of a field that has received prior irradiation when the above medical necessity criteria has been met ⁶³

3. **Exclusions:** Other uses of IMRT are considered experimental, investigational and unproven due to insufficient peer reviewed medical literature for the treatment of any other condition not outlined above.

The peer reviewed medical evidence from randomized controlled trials, prospective and retrospective studies is sufficient to determine the safety and efficacy of IMRT as a treatment for primary brain tumors, brain metastasis, prostate cancer, lung cancer, spinal cord tumors, head and neck cancer, adrenal tumors, and pituitary tumors where extremely high radiation precision is required. Other indications for IMRT include some left breast tumors due to risk to immediately adjacent cardiac and pericardial structures. There is a large body of literature therefore only a summary of the most relevant studies is provided below.

IMRT is an emerging technology and is being studied in other thoracic tumors, abdominal tumors, esophageal and tracheal tumors, gynecologic tumors such as cervical cancer, anal cancer and in other genitourinary tumors where its high precision is especially necessary to avoid immediately adjacent structures such as heart, bowel or where there is a special need to avoid marrow. There is an increasing body of evidence in the peer reviewed medical literature that is demonstrating a positive impact of IMRT on patient health outcomes for these conditions.

Breast Cancer

The published literature on IMRT for the treatment of breast cancer suggests that whole breast irradiation (WBI) by intensity-modulated radiation therapy (IMRT) using standard fractionation schedules has lower rates of acute toxicity than standard two-dimensional (2D) radiation therapy in patients with early-stage breast cancer. Randomized controlled trials with sample sizes from 306 to 815 participants and follow-up times ranged from 6 weeks to 6.3 years show that WBI using IMRT delivered on a standard fractionation schedule for treatment of patients with early-stage breast cancer who have undergone breast-conserving surgery may be appropriate specifically in patients with left breast tumors when sparing surrounding tissue due to risk of immediately adjacent cardiac and pericardial structures.⁷⁻⁸⁻¹⁷⁻³⁹⁻⁴⁶

Central Nervous System (CNS)

The published evidence on IMRT for the treatment of CNS tumors consistently report better sparing of healthy tissues and reduced toxicity in IMRT-treated patients and suggest that IMRT provides tumor control and survival outcomes comparable to existing radiotherapy techniques. Retrospective and prospective trials with sample sizes from 25-200 participants and follow-up times up to 2 years show that in most IMRT series excellent compliance and low rates of toxicity were recorded. Hypofractionated regimens in association with chemotherapy showed results that are even superior to the standard treatment.⁵⁻¹⁸⁻²⁶⁻³²⁻³³⁻⁴⁸

Prostate Cancer

The published literature on IMRT for the treatment of prostate cancer reports that IMRT may permit the delivery of higher doses of radiation to the prostate with relatively little toxicity to surrounding tissues and that higher radiation doses resulted in improved local tumor control, biochemical outcomes, and biopsy findings. IMRT is also associated with a significant reduction in acute GI/GU toxicity. Randomized controlled trials with sample sizes from 100 to 12,976 participants and follow-up times up to 5 years show that high-dose IMRT was feasible and safe, improved dose conformality relative to tumor coverage and exposure to normal tissue, and had a lower risk of late moderate rectal bleeding.³⁻²⁰⁻²¹⁻²⁵⁻⁴²⁻⁴⁷

Head and Neck Cancer

The published literature on IMRT for the treatment of head and neck cancers (oral cavity and lip, larynx, hypopharynx, oropharynx, nasopharynx, paranasal sinuses and nasal cavity, salivary glands, and occult primaries in the head and neck region) reports that IMRT provides tumor control rates comparable to existing radiotherapy techniques. Randomized controlled trials, prospective and retrospective studies with sample sizes from 50 to 250 participants and follow-up times from 2 - 5 years show that IMRT may reduce the risk of exposure to radiation in critical nearby structures, such as spinal cord, salivary glands, and esophagus, thus decreasing risks of adverse effects such as xerostomia and esophageal stricture. The 5-year local control, overall survival, disease-specific survival, disease-free survival, and freedom from distant metastasis rate was 70.7%, 58.5%, 67%, 59.3%, and 82.2%, respectively. ⁴⁻¹¹⁻¹⁶⁻⁴⁵⁻⁵⁹

Lung Cancer

The published literature on IMRT for the treatment of lung cancer suggests that IMRT should be considered for lung cancer patients where the tumor is in close proximity to an organ at risk, where the target volume includes a large volume of an organ at risk, or in scenarios where dose escalation would be potentially beneficial while minimizing normal tissue toxicity. Evidence from systematic reviews, retrospective and prospective studies with sample sizes from 50 to 400 participants and follow-up times from 2 - 3 years report significant reduction in toxicity and improvement in survival. Median overall survival time was 1.8 years; the 2-year and 3-year overall survival rates were 46% and 30%, respectively. ¹⁰⁻²²⁻³⁴⁻³⁵⁻³⁸⁻⁵⁰

Cervical Cancer ¹³⁻¹⁵⁻⁴⁰

Published literature from a Phase III randomized study (Chopra et al 2015), of three dimensional conformal radiation (3DCRT) vs. image guided radiation therapy (IGIMRT) was initiated in with a primary aim to demonstrate reduction in grade ≥ 2 late bowel toxicity in patients undergoing adjuvant chemoradiation for cervical cancer. A total of 120 patients completed a median follow up of 20 months (2–46). For cervical cancer patients undergoing postsurgical radiation therapy, image-guided intensity-modulated radiation therapy (IMRT) resulted in a 14% reduction in moderate-to-severe bowel side effects when compared to conventional three-dimensional conformal radiation therapy (3D CRT). ¹⁵

Mediastinal Tumors

In 2011 Koeck conducted a comparative treatment planning analysis according to the guidelines of the German Hodgkin Study Group. This study analyzed the impact of target volume reduction with involved node (IN) RT vs. involved field (IF) RT and 3D-CRT vs. IMRT in 20 subjects with early unfavorable mediastinal Hodgkin's lymphoma (HL) for achievable plan quality, treatment efficiency and degree of sparing of organs at risk for radiation exposure. Dose-volume histograms (DVH) were evaluated for planning target volumes (PTV) and organs at risk (OAR). Results showed almost identical mean dose to the PTV for all radiation plans. For the IF and IN PTVs, target conformity was better with IMRT but homogeneity was better with 3D-CRT. The authors concluded that the findings demonstrated a pronounced benefit with IMRT for irradiation of lymph nodes anterior to the heart. Reduction of target volumes to IN-PTV most effectively improved OAR sparing regardless of the RT technique. ²⁸

CODING INFORMATION THE CODES LISTED IN THIS POLICY ARE FOR REFERENCE PURPOSES ONLY. LISTING OF A SERVICE OR DEVICE CODE IN THIS POLICY DOES NOT IMPLY THAT THE SERVICE DESCRIBED BY THIS CODE IS COVERED OR NON-COVERED. COVERAGE IS DETERMINED BY THE BENEFIT DOCUMENT. THIS LIST OF CODES MAY NOT BE ALL INCLUSIVE.

CPT	Description
77301	Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications
77338	Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy
77385	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple
77386	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex
77387	Guidance for localization of target volume for delivery of radiation treatment delivery, includes intrafraction tracking, when performed

HCPCS	Description
G6015	Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session
G6016	Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session

ICD-10	Description: [For dates of service on or after 10/01/2015]
C00-D49	Neoplasms code range

REFERENCES

Government Agencies

- Centers for Medicare & Medicaid Services. Medicare Coverage Database. Intensity Modulated Radiation Therapy (IMRT) LCD# L24318 & L34080. Effective 9/1/2014. Accessed at: <http://www.cms.gov/medicare-coverage-database/>
- Food and Drug Administration (FDA) [website]. Center for Devices and Radiological Health (CDRH). Search 510(k) Database for IMRT systems. Product Codes MUY, IYE or LHN . Accessed at: <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/PMNSimpleSearch.cfm>.
- Agency for Healthcare Research and Quality. Intensity-modulated radiation therapy for localized prostate cancer yields fewer side effects than other radiation treatments. No. 387. November, 2012. Accessed at: <http://www.ahrq.gov/news/newsletters/research-activities/12nov/1112ra23.html>
- Agency for Healthcare Research and Quality Samson, DM, Ratko, TA, Rothenberg, BM, et al. Comparative effectiveness and safety of radiotherapy treatments for head and neck cancer. Comparative Effectiveness Review No. 20. May, 2010. Accessed at: www.effectivehealthcare.ahrq.gov/reports/final.cfm

Peer Reviewed Publications

5. Amelio, D, Lorentini, S, Schwarz, M, Amichetti, M. Intensity-modulated radiation therapy in newly diagnosed glioblastoma: a systematic review on clinical and technical issues. *Radiother Oncol.* 2010 Dec;97(3):361-9. PMID: 20926149
6. Barillot I, Tavernier E, Peignaux K et al. Impact of post-operative intensity modulated radiotherapy on acute gastro-intestinal toxicity for patients with endometrial cancer: results of the phase II RTCMIENDOMETRE French multicentre trial. *Radiother Oncol.* 2014 Apr;111(1):138-43
7. Barnett GC, Wilkinson J, Moody AM, et al. A randomised controlled trial of forward-planned radiotherapy (IMRT) for early breast cancer: baseline characteristics and dosimetry results. *Radiother Oncol.* 2009;92(1):34-41.
8. Barnett GC, Wilkinson JS, Moody AM, et al. Randomized controlled trial of forward-planned intensity-modulated radiotherapy for early breast cancer: interim results at 2 years. *Int J Radiat Oncol Biol Phys.* 2012;82(2):715-723.
9. Bazan JG, Hara W, Hsu A, et al. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. *Cancer* 2011; 117:3342.
10. Bezjak, A, Rumble, RB, Rodrigues, G, Hope, A, Warde, P. Intensity-modulated radiotherapy in the treatment of lung cancer. *Clin Oncol (R Coll Radiol).* 2012 Sep;24(7):508-20. PMID: 22726417
11. Bhatia, A, Rao, A, Ang, KK, et al. Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. *Head Neck.* 2010 Jul;32(7):829-36. PMID: 19885924
12. Call JA, Prendergast BM, Jensen LG et al. Intensity-modulated Radiation Therapy for Anal Cancer: Results From a Multi-Institutional Retrospective Cohort Study. *Am J Clin Oncol.* 2014 Jan 7.
13. Chen, MF, Tseng, CJ, Tseng, et al. Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent Cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy. *Int J Radiat Oncol Biol Phys.* 2007a;67(5):1438-1444.
14. Chen YJ, Liu A, Han C, et al. Helical tomotherapy for radiotherapy in esophageal cancer: a preferred plan with better conformal target coverage and more homogeneous dose distribution. *Med Dosim.* 2007b; 32(3):166-171.
15. Chopra S, Engineer R, Mahantshetty UM, et al. Phase III RCT of Postoperative Adjuvant Conventional Radiation (3DCRT) Versus IGIMRT for Reducing Late Bowel Toxicity in Cervical Cancer (PARCER) (NCT01279135/CTRI2012/120349): Results of Interim Analyses. *Int Journal Rad Onc.* November 1, 2015 Volume 93, Issue 3, Supplement, P-S4
16. Dirix, P, Nuyts, S. Value of intensity-modulated radiotherapy in Stage IV head-and-neck squamous cell carcinoma. *Int J Radiat Oncol Biol Phys.* 2010 Dec 1;78(5):1373-80. PMID: 20362402
17. Donovan E, Bleakley N, Denholm E, et al.; Breast Technology Group. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. *Radiother Oncol.* 2007;82(3):254-264.
18. Fuller CD, Choi M, Forthuber B, et al. Standard fractionation intensity modulated radiation therapy (IMRT) of primary and recurrent glioblastoma multiforme. *Radiat Oncol.* 2007;2:26.
19. Gandhi AK, Sharma DN, Rath GK et al. Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study. *Int J Radiat Oncol Biol Phys.* 2013 Nov 1;87(3):542-8.
20. Goldin G, Sheets N, Meyer A et al. Comparative effectiveness of intensity-modulated radiotherapy and conventional conformal radiotherapy in the treatment of prostate cancer after radical prostatectomy. *JAMA.* 2013, June 13;173(12), pp. 1136-1143.
21. Goldin G, Sheets N, Meyer A et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. *JAMA.* 2012, April 18, 2012; 307(15), pp. 1611-1620.

22. Govaert, SL, Troost, EG, Schuurbiens, OC, et al. Treatment outcome and toxicity of intensity-modulated (chemo) radiotherapy in stage III non-small cell lung cancer patients. *Radiat Oncol*. 2012;7:150. PMID: 22958781
23. Han K, Cummings BJ, Lindsay P, et al. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer. *Int J Radiat Oncol Biol Phys* 2014; 90:587.
24. Hasselle MD, Rose BS, Kochanski JD, et al. Clinical outcomes of intensity-modulated pelvic radiation therapy for carcinoma of the cervix. *Int J Radiat Oncol Biol Phys*. 2011 Aug 1;80(5):1436-45.
25. Hoffman KE, Voong KR, Pugh TJ, et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. *Int J Radiat Oncol Biol Phys*. 2014 Apr 1; 88(5):1074-84. doi: 10.1016/j.ijrobp.2014.01.015
26. Hu X, Fang Y, Hui X, et al. Radiotherapy for diffuse brainstem glioma in children and young adults. *Cochrane Database Syst Rev*. 2016;(6):CD010439.
27. Huang CM, Huang MY, Tsai HL, et al. A retrospective comparison of outcome and toxicity of preoperative image-guided intensity-modulated radiotherapy versus conventional pelvic radiotherapy for locally advanced rectal carcinoma. *J Radiat Res*. 2017 Mar 1;58(2):247-259. doi: 10.1093/jrr/rrw098
28. Koeck J, Abo-Madyan Y, Lohr F, et al. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy. *Int J Radiat Oncol Biol Phys*. 2012; 83(1):268-276.
29. Kole T, Aghayere O, Kwah J, et al. Comparison of heart and coronary artery doses associated with intensity-modulated radiation therapy versus three-dimensional conformal radiotherapy for distal esophageal cancer. *Int J Radiat Oncol Biol Phys*. 2012; 83(5): 1580-1586.
30. La TH, Minn AY, Su Z, et al. Multimodality treatment with intensity modulated radiation therapy for esophageal cancer. *Dis Esophagus*. 2010; 23(4): 300-308.
31. Lin SH, Wang L, Myles B, et al. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. *Int J Radiat Oncol Biol Phys*. 2012; 84(5): 1078-1085.
32. Iuchi T, Hatano K, Kodama T, et al. Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. *Int J Radiat Oncol Biol Phys*. 2014 Mar 15 ;88(4):793-800. doi: 10.1016/j.ijrobp.2013.12.011. Epub 2014 Feb 1
33. Iuchi T, Hatano K, Narita Y, et al. Hypofractionated high-dose irradiation for the treatment of malignant astrocytomas using simultaneous integrated boost technique by IMRT. *Int J Radiat Oncol Biol Phys*. 2006;64(5):1317-1324.
34. Jensen, AD, Munter, MW, Bischoff, HG, et al. Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab: The NEAR trial. *Cancer*. 2010 Jan 24. PMID: 21264838
35. Jiang, ZQ, Yang, K, Komaki, R, et al. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience. *Int J Radiat Oncol Biol Phys*. 2012 May 1;83(1):332-9. PMID: 22079735
36. Kachnic LA, Tsai HK, Coen JJ, et al. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. *Int J Radiat Oncol Biol Phys* 2012; 82:153.
37. Kachnic LA, Winter K, Myerson RJ, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. *Int J Radiat Oncol Biol Phys* 2013; 86:27.
38. Liao, ZX, Komaki, RR, Thames, HD, Jr., et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. *Int J Radiat Oncol Biol Phys*. 2010 Mar 1;76(3):775-81. PMID: 19515503

39. Livi L, Buonamici FB, Simontacchi G, et al. Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized clinical trial. *Int J Radiat Oncol Biol Phys.* 2010;77(2):509-515.
40. Lv Y1Wang F et al. Intensity-modulated whole pelvic radiotherapy provides effective dosimetric outcomes for cervical cancer treatment with lower toxicities. *Cancer Radiother.* 2014 Dec;18(8):745-52
41. Madani I, Bonte K, Vakaet L, Boterberg T, De Neve W. Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update. *Int J Radiat Oncol Biol Phys.* 2009;73(2):424-432.
42. Michalski JM1, Yan Y, Watkins-Bruner D, et al. Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. *Int J Radiat Oncol Biol Phys.* 2013 Dec 1 ;87(5):932-8. doi: 10.1016/j.ijrobp.2013.07.041. Epub 2013 Oct 8
43. Mitchell MP, Abboud M, Eng C et al. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. *Am J Clin Oncol.* 2014 Oct;37(5):461-6. doi: 10.1097/COC.0b013e31827e52a3.
44. Nour AA, Alaradi A et al. Intensity modulated radiotherapy of upper abdominal malignancies: dosimetric comparison with 3D conformal radiotherapy and acute toxicity. *Radiat Oncol.* 2013 Sep 5;8:207
45. Nutting, CM, Morden, JP, Harrington, KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. *Lancet Oncol.* 2011 Feb;12(2):127-36. PMID: 21236730
46. Pignol JP, Olivotto I, Rakovitch E, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. *J Clin Oncol.* 2008;26(13):2085-2092.
47. Pollack A, Hanlon AL, Horwitz EM, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. *Int J Radiat Oncol Biol Phys.* 2006;64(2):518-526.
48. Press RH, Prabhu RS, Appin CL, et al. Outcomes and patterns of failure for grade 2 meningioma treated with reduced-margin intensity modulated radiation therapy. *Int J Radiat Oncol Biol Phys.* 2014 Apr 1 ;88(5):1004-10. doi: 10.1016/j.ijrobp.2013.12.037
49. Salama JK, Mell LK, Schomas DA, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. *J Clin Oncol* 2007; 25:4581.
50. Sura, S, Gupta, V, Yorke, E, Jackson, A, Amols, H, Rosenzweig, KE. Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. *Radiother Oncol.* 2008 Apr;87(1):17-23. PMID: 18343515
51. Vergeer, MR, Doornaert, PA, Rietveld, DH, Leemans, CR, Slotman, BJ, Langendijk, JA. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program. *Int J Radiat Oncol Biol Phys.* 2009 May 1;74(1):1-8. PMID: 19111400
52. Wiegner EA, Daly ME, Murphy JD, et al. Intensity-modulated radiotherapy for tumors of the nasal cavity and paranasal sinuses: clinical outcomes and patterns of failure. *Int J Radiat Oncol Biol Phys.* 2012;83(1):243-251.

Hayes

53. Hayes Health Technology Brief. Winifred Hayes, Inc. Lansdale, PA.
 - Postoperative Intensity-Modulated Radiation Therapy for Sinus Cancers. Winifred Hayes, Inc. Lansdale, PA. Updated November 26, 2014. Updated 2015. Archived 2017.
 - Intensity-Modulated Radiation Therapy (IMRT) for Malignant Gliomas. Last updated August, 2010. Archived 2011.
54. Hayes Medical Technology Directory. Winifred Hayes, Inc. Lansdale, PA.

- Accelerated Partial Breast Irradiation for Breast Cancer Using Conformal and Intensity-Modulated Radiation Therapy. March 12, 2012. Updated March 14, 2014. Updated 2018.
 - Whole Breast Irradiation for Breast Cancer Using Three- Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy. March 8, 2012. Updated 2016. Archived 2017.
 - Conformal and Intensity-Modulated Radiation Therapy for Prostate Cancer. Last updated Nov, 2010. Archived 2011.
 - Conformal and Intensity-Modulated Radiation Therapy for Pancreatic Cancer Winifred Hayes, Inc. Lansdale, PA. Last updated Nov, 2010. Archived 2012.
 - Conformal and Intensity-Modulated Radiation Therapy for Pancreatic Cancer. Last updated Nov, 2010. Archived 2012.
 - Intensity Modulated Radiation Therapy (IMRT) for Anal or Rectal Cancer. 2015. Updated 2018.
55. Hayes Search & Summary. Winifred Hayes, Inc. Lansdale, PA.
- Intensity-Modulated Radiation Therapy (IMRT) for Colon Cancer. July 2014.
 - Intensity Modulated Radiation Therapy (IMRT) for Anal or Rectal Cancer. Feb 2015
 - Intensity Modulated Radiation Therapy (IMRT) for Urinary Bladder Cancer. June 2015

Professional Organizations

56. American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO). Practice Guideline for Intensity Modulated Radiation Therapy (IMRT). 2014. Revised 2016. Accessed at: <https://www.acr.org/>
57. American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO). Model Policy: Intensity Modulated Radiation Therapy (IMRT). 2013. Updated 12/2015. Last Update June, 2019. Accessed at: <https://www.astro.org/ASTRO/media/ASTRO/Daily%20Practice/PDFs/IMRTMP.pdf>
58. American College of Radiology (ACR) Appropriateness Criteria Anal Cancer. Expert Panel on Radiation Oncology–Rectal/Anal Cancer. *Gastrointest Cancer Res.* 2014 Jan-Feb; 7(1): 4–14. Accessed at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924766/>
59. O'Sullivan B, Rumble RB, Warde P, IMRT Indications Expert Panel. The role of IMRT in head & neck cancer. Toronto (ON): Cancer Care Ontario (CCO); 2011 Jan 12. (Evidence-based series; no. 21-3-3).
60. Catton C, Rumble RB, Warde P, IMRT Indications Expert Panel. The role of IMRT in soft-tissue sarcomas. Toronto (ON): Cancer Care Ontario (CCO); 2010 Oct 29. (Evidence-based series; no. 21-3-6).
61. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. 2017-2019. Accessed at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
- Head and Neck Cancers.
 - Breast Cancer.
 - Nervous System Cancers.
 - Non-Small Cell Lung Cancer and Small Cell Lung Cancer.
 - Prostate cancer.
 - Anal Carcinoma.
 - Cervical Cancer.
 - Esophageal and Esophagogastric Junction Cancers.
 - Soft Tissue Sarcoma
 - Uterine Neoplasms

Other Resources

62. UpToDate: [website]: Waltham, MA. Walters Kluwer Health; 2019.
- Song S. General principles of radiation therapy for head and neck cancer.
 - Dibase S, Roach M. External beam radiation therapy for localized prostate cancer.
 - Ryan D, Willet C. Clinical features, staging, and treatment of anal cancer.
63. Advanced Medical Review (AMR): Policy reviewed by a practicing MD Board certified in Radiation Oncology. January 16, 2015 & January 12, 2018.

Revision/Review History:

3/25/15: New Policy

6/24/15: The policy was reviewed and revised to incorporate two new clinical indications for IMRT: Rectal/Anal cancer and abdominal and pelvic tumors.

12/16/15, 9/15/16 & 6/22/17: Policy reviewed, no changes to criteria.

3/18/18: The following medical necessity criteria for IMRT was added for these indications: orbits and tracheal cancer; esophageal cancer, mediastinal tumors; cervical or uterine cancer in patients who have had a hysterectomy with intact cervix when the para-aortic lymph nodes require treatment; left breast cancer when 3D conformal produces focal regions with dose variation greater than 10% of target and for patients with target tissues that include the far medial chest wall, internal mammary nodal area or sternum (post-mastectomy or post lumpectomy); rectal/anal cancer in unique clinical situations such as re-irradiation of previously treated recurrent disease or unique anatomical situations; soft tissue sarcoma when an R1 or R2 resection is anticipated to increase the therapeutic ratio and repeat irradiation of a field that has received prior irradiation when the above medical necessity criteria has been met.

9/18/19: Policy reviewed, no changes to criteria.